Phacilitate and Biolacuna have produced a cutting-edge report, which includes the results, data and analysis of an industry-wide survey, plus interviews with world-leading experts.
Successful automation is going to change the game for advanced therapies by controlling the cost of goods and improving standardisation, particularly in manufacturing.
It's no secret that commercially successful cell-based therapy bioprocessing demands quality, consistency and scalability, which is why Phacilitate's Automation Special Interest Group was launched in 2017 during which the focus was firmly on creating a roadmap towards automation in cell-based therapy manufacturing and supply chains. A 57-page report was produced based on the working group results at the SIG and some follow up research and industry surveys.
However, we don't all have time for a 57-page report! To give you the headline findings and to help you decide whether to purchase the full report, you can visualise them on one page here.